Abstract 4913
Background
Patients with carcinoma prostate undergo rapid decline in bone health as measured by bone mineral density in the first 6 to 12 months of treatment with androgen deprivation. The WHO has developed the FRAX (Fracture Risk Assessment) Tool to predict long-term risk of major fractures and hip fracture. Guidelines are available for managing therapy related osteoporosis. This study is to characterize the risk (based on the FRAX tool) and management on the basis of guidelines in view of non-availability of bone matrix density assessments on basis of DEXA Scan.
Methods
A retrospective analysis of 196 consecutive patients receiving LHRH agonists at a single practice for the period of 2010 to 2018 was done. Data was collected after IRB clearance and included demographics, medical history, treatment history, history of ADT, bone health and its management. 10y fracture risk was calculated using the FRAX tool. Descriptive statistics were used for demographic analysis and to characterise the management of bone health. Paired t-Test was used to compare 10y fracture pre and post ADT.
Results
A total of 196 patients were seen. The mean age was 65.5y. 36% patients had Stage II disease and 56% had Stage III disease. All patients had PSA >10 and a Gleason Score >7 and Life expectancy <10y. 97% patients received LHRH agonists for a mean period of 13.8 + 18.1 months. 57% patients had >2 Risk for osteoporosis. Counselling for adverse effect of ADT and bone side effects was seen in 20% of patients. Bone health assessment was not available for 75% of patients. Bisphosphonate therapy was seen in 3% of patients. The risk of sustaining a major fracture increased from 26% to 34% (P < 0.001) on initiation of ADT. The risk of sustaining a hip fracture rose from 12% to 20%. Guidelines was followed for DEXA Scan, Calcium supplements and Vitamin D in 22%, 15%, and 8% respectively.
Conclusions
In addition to predisposing factors of osteoporosis, ADT increases risk of fracture in patients with ca prostate. There is room for improvement by increasing health literacy in multi-disciplinary team and Care providers. This is the first paper of its kind in developing countries including quality practice audit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
G S Bhattacharyya.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1269 - One-year follow-up results of eribulin for soft-tissue sarcoma including rare subtypes in a real-world observational study in Japan
Presenter: Shunji Takahashi
Session: Poster Display session 1
Resources:
Abstract
2868 - Prevalence of chemotherapy use and its impact on overall survival in patients with bone- and soft tissue sarcomas -A population-based analysis of 3746 patients
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract
3042 - Clinical course and therapeutic management of classical and endemic Kaposi’s Sarcoma (C/E KS)
Presenter: Lina Benajiba
Session: Poster Display session 1
Resources:
Abstract
3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma
Presenter: Katarzyna Kozak
Session: Poster Display session 1
Resources:
Abstract
5449 - Real-world Outcomes of Patients with Locally Advanced or Metastatic Epithelioid Sarcoma
Presenter: Mrinal Gounder
Session: Poster Display session 1
Resources:
Abstract
4465 - SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): results from the phase I part of a phase I/II trial
Presenter: Antonia Digklia
Session: Poster Display session 1
Resources:
Abstract
5013 - Outcome of 98 patients with epithelioid sarcoma treated in curative intent: a retrospective study from the French Sarcoma Group (GSF-GETO)
Presenter: Maud Pedrono
Session: Poster Display session 1
Resources:
Abstract
5614 - Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy.
Presenter: Paolo Tarantino
Session: Poster Display session 1
Resources:
Abstract
1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe
Presenter: Vasilii Ostafiichuk
Session: Poster Display session 1
Resources:
Abstract
4094 - Treatment outcomes for adult patients with localized osteosarcoma treated with chemotherapy without methotrexate
Presenter: Marília Silva
Session: Poster Display session 1
Resources:
Abstract